# A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

> **NCT05261191** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 17 (actual)

## Conditions studied

- Human Immunodeficiency Virus I Infection
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1

## Interventions

- **BIOLOGICAL:** MGD020
- **BIOLOGICAL:** MGD014

## Key facts

- **NCT ID:** NCT05261191
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-26
- **Primary completion:** 2024-05-29
- **Final completion:** 2024-05-29
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261191, "A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05261191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*